ModiQuest applies innovative technologies including differential proteomics in the identification of disease related protein modifications. ModiQuest uses automated high-throughput B-cell selection, highly efficient electrofusion methods, and recombinant antibody technology for the generation of corresponding diagnostic and/or therapeutic monoclonal antibodies.

 

Modiquest’s sister company Modiquest Research provides contract research in antibody discovery, development and  production.